The board of directors of Shanghai Junshi Biosciences Co., Ltd. announced that Mr. Li Cong ("Mr. Li") has been re-designated from a non-executive Director to an executive Director of the Company and has appointed as the co-chief executive officer (the "Co-CEO") of the Company with effect from 2 November 2021. Mr. Li's biographical details are set out as follows: Mr. Li Cong aged 57, was appointed as a non-executive Director on 22 December, 2016 and has been re-designated as an executive Director of the Company and appointed as a Co-CEO of the Company on 2 November 2021. From January 2004 to March 2019, he held the positions of regional manager, sales director and general manager at Tonghua Dongbao Pharmaceutical Co., Ltd. (a company listed on the Shanghai Stock Exchange (stock code: 600867.SH)). Since June 2019, he has held the positions of director and general manager of Suzhou Landing Biosciences Co. Ltd. and the responsible person of the Shanghai branch of Suzhou Landing. Mr. Li obtained his bachelor's degree in medicine from Shanghai Tiedao University School of Medicine (now known as Tongji University School of Medicine), the PRC in July 1986. Mr. Li has been re-designated from a non-executive Director to an executive Director of the Company with effect from 2 November 2021. Upon the Re-designation, Mr. Li ceased to be a member of the audit committee of the Company with effect from 2 November 2021. Following the Re-designation, the Board will comprise fourteen members with six executive Directors, three non-executive Directors and five independent non-executive Directors. The Board announced that, Mr. Tang Yi, being an existing non-executive Director of the Company, has been appointed as a member of the Audit Committee with effect from 2 November 2021. The Board would like to welcome Mr. Li and Mr. Tang Yi taking up the new positions.